Loading patent…
AssigneesThe Institute for Human Genetics and Biochemistry, Cynthia Bristow
InventorCynthia L. Bristow
Estimating the term…
A previously unrecognized fundamental property of α1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of α1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of α1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.
A method for increasing the number of functional lymphocytes, monocytes, or dendritic cells of comprising administering to a subject in need of such treatment a pharmaceutical composition containing full length, active α1 proteinase inhibitor (αl PI) having the amino acid sequence set forth in SEQ ID NO:
A method for mobilizing lymphoid-lineage progenitor cells into circulation in a patient in need of such treatment comprising administering to said patient a composition containing an amount of full length, active α1 PI having the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.